When AI designs a drug, who gets the credit?

Insilico Medicine claims its AI discovered a new drug for pulmonary fibrosis, which triggers a massive fight over intellectual property. If a machine finds the molecule, current patent laws might not recognize it as an invention.

This is a potential death blow for AI-first biotech valuations. If the IP isn't protectable, the entire business model of generative drug discovery loses its foundation.

This will shift capital from pure model companies to those building defensible discovery platforms that integrate heavily with human researchers.

• →Build verification tools that document human-in-the-loop decision making for patent filings
• →Create platforms that focus on the validation stage, turning AI outputs into clinically ready assets
• →Develop hybrid models that explicitly credit human researchers to ensure legal IP defensibility

• →Patent offices may reject AI-generated molecules, rendering massive R&D investments worthless
• →Large pharma could use AI as a commodity tool, turning specialized startups into low-margin service providers